Churning, Confusion And Disruption — The Dark Side Of Marketplace Coverage
The Affordable Care Act has increased the number of people with insurance, but shopping around for plans puts a burden on patients, especially this year.
Everyone Says We Must Control Exorbitant Drug Prices. So, Why Don’t We?
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
Taking A U-Turn On Benefits, Big Employers Vow To Continue Offering Health Insurance
Three years ago, only about a quarter of the nation’s large employers were very confident they would have a health plan in 10 years. That number has now risen to 65 percent.
Despite Insurers’ Tactical Win On ACA’s Cost-Sharing Payments, Uncertainty Lingers
Court allows state attorneys general to join a pending legal challenge to keep billions in subsidies flowing to consumers and insurers, despite the Trump administration’s resistance.
Follow The Money: Drugmakers Deploy Political Cash As Prices And Anger Mount
Embattled opioid seller Mallinckrodt is one of many pharmaceutical companies boosting political contributions and lobbying on Capitol Hill.
Analysis: Senate’s Latest Health Blueprint Cuts Costs At The Expense Of Chronically Ill
The Senate draft bill released Thursday to replace the Affordable Care Act risks creating a high-cost ghetto for those with preexisting conditions or long-term sickness, experts say.
Promises Made To Protect Preexisting Conditions Prove Hollow
Experts say the loopholes would allow states to bypass some protections for people with preexisting conditions.
Huecos en las promesas de proteger la cobertura de condiciones preexistentes
Expertos en políticas de salud que han analizado el texto del proyecto de salud del Senado, aseguran que la legislación no siempre garantizaría la atención de personas con condiciones preexistentes.
Former Pharma Reps’ New Mission: To School Docs On High Drug Costs
One insurer is turning the tables on drugmakers with what may be a new job category: a sales force for cost-effective medicine.
With Drug Costs In Crosshairs, Health Firms Gave Generously To Trump’s Inauguration
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.